ERBB2 and breast cancer: To our knowledge, this is the first study to evaluate the possible prognostic and predictive significance of MYC and KRAS alterations concomitantly with HR and HER2 status, in BC patients treated with neoadjuvant doxorubicin plus cyclophosphamide drugs.